ES2240829T3 - Derivados de piridina como ligandos receptores de nmda. - Google Patents

Derivados de piridina como ligandos receptores de nmda.

Info

Publication number
ES2240829T3
ES2240829T3 ES02787541T ES02787541T ES2240829T3 ES 2240829 T3 ES2240829 T3 ES 2240829T3 ES 02787541 T ES02787541 T ES 02787541T ES 02787541 T ES02787541 T ES 02787541T ES 2240829 T3 ES2240829 T3 ES 2240829T3
Authority
ES
Spain
Prior art keywords
formula
pyridin
dihydro
isoquinolin
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES02787541T
Other languages
English (en)
Spanish (es)
Inventor
Alexander Alanine
Bernd Buettelmann
Marie-Paule Heitz Neidhart
Emmanuel Pinard
Rene Wyler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2240829T3 publication Critical patent/ES2240829T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ES02787541T 2001-11-09 2002-11-02 Derivados de piridina como ligandos receptores de nmda. Expired - Lifetime ES2240829T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01126467 2001-11-09
EP01126467 2001-11-09

Publications (1)

Publication Number Publication Date
ES2240829T3 true ES2240829T3 (es) 2005-10-16

Family

ID=8179179

Family Applications (1)

Application Number Title Priority Date Filing Date
ES02787541T Expired - Lifetime ES2240829T3 (es) 2001-11-09 2002-11-02 Derivados de piridina como ligandos receptores de nmda.

Country Status (16)

Country Link
US (1) US6831087B2 (enExample)
EP (1) EP1448547B1 (enExample)
JP (1) JP4188837B2 (enExample)
KR (1) KR100589995B1 (enExample)
CN (1) CN100516061C (enExample)
AR (1) AR037221A1 (enExample)
AT (1) ATE293619T1 (enExample)
AU (1) AU2002351816B8 (enExample)
BR (1) BR0213977A (enExample)
CA (1) CA2467973C (enExample)
DE (1) DE60203820T2 (enExample)
ES (1) ES2240829T3 (enExample)
MX (1) MXPA04004308A (enExample)
PL (1) PL369544A1 (enExample)
RU (1) RU2303037C2 (enExample)
WO (1) WO2003040128A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799832B2 (en) * 2003-10-23 2010-09-21 Valeant Pharmaceuticals North America Combinations of retigabine and sodium channel inhibitors or sodium channel-influencing active compounds for treating pains
JP2007008816A (ja) * 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
RU2320654C1 (ru) * 2006-05-24 2008-03-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная фармацевтическая академия Федерального агентства по здравоохранению и социальному развитию" (ГОУ ВПО ПГФА Росздрава) 2,2-ДИМЕТИЛ-4-(4,6-ДИМЕТИЛ-2-ПИРИДОН-3-ИЛ)-1,2-ДИГИДРО-БЕНЗО[f]ИЗОХИНОЛИНА ГИДРОХЛОРИД, ПРОЯВЛЯЮЩИЙ ПРЯМОЕ АНТИКОАГУЛЯНТНОЕ ДЕЙСТВИЕ
US8722929B2 (en) * 2006-10-10 2014-05-13 Valeant Pharmaceuticals International N-[2-amino-4-(phenylmethoxy)phenyl] amides and related compounds as potassium channel modulators
US8367684B2 (en) * 2007-06-13 2013-02-05 Valeant Pharmaceuticals International Derivatives of 4-(N-azacycloalkyl) anilides as potassium channel modulators
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
US7786146B2 (en) * 2007-08-13 2010-08-31 Valeant Pharmaceuticals International Derivatives of 5-amino-4,6-disubstituted indole and 5-amino-4,6-disubstituted indoline as potassium channel modulators
NZ585347A (en) 2007-10-18 2011-09-30 Boehringer Ingelheim Int Cgrp antagonists
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
EP2062889A1 (de) * 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Verbindungen
EP2225237A2 (de) * 2007-11-22 2010-09-08 Boehringer Ingelheim International GmbH Organische verbindungen
EP2225223B1 (de) 2007-11-22 2017-01-11 Boehringer Ingelheim International GmbH Organische verbindungen
EA014100B1 (ru) * 2008-02-21 2010-08-30 Общество С Ограниченной Ответственностью "Валексфарм" Производные 2,4-диаминопиридина, фармацевтическая композиция, лекарственное средство на их основе для лечения или предупреждения заболеваний и нарушений, вызванных гиперактивацией nmda-рецепторов и/или в качестве стимуляторов когнитивных функций и способ лечения
RU2438672C1 (ru) * 2010-04-30 2012-01-10 Общество с ограниченной ответственностью "Клевер Фарм" Агент, проявляющий свойства активатора когнитивных функций (варианты)
CN122422302A (zh) * 2023-12-14 2026-07-17 斯莱普泰(上海)生物医药科技有限公司 Nmda受体拮抗剂及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9610738B (en) 1995-12-22 1997-06-24 Warner Lambert Co Subtype selective nmda receptor ligands and the use thereof
ATE524440T1 (de) * 1998-05-25 2011-09-15 Abbott Gmbh & Co Kg Heterocyclische substituierte amide, deren herstellung und anwendung
US6440995B1 (en) * 1999-10-01 2002-08-27 Hoffman-La Roche Inc. Quinolin-4-yl derivatives
EP1088818B1 (en) 1999-10-01 2004-11-03 F. Hoffmann-La Roche Ag Quinolin-4-yl derivatives
US6339093B1 (en) 1999-10-08 2002-01-15 Hoffmann-La Roche Inc. Isoquinoline derivatives

Also Published As

Publication number Publication date
MXPA04004308A (es) 2004-08-11
DE60203820D1 (de) 2005-05-25
KR20050042252A (ko) 2005-05-06
EP1448547B1 (en) 2005-04-20
KR100589995B1 (ko) 2006-06-19
CA2467973A1 (en) 2003-05-15
JP4188837B2 (ja) 2008-12-03
AU2002351816B8 (en) 2008-04-03
PL369544A1 (en) 2005-05-02
RU2004117595A (ru) 2006-01-10
AR037221A1 (es) 2004-10-27
CA2467973C (en) 2009-09-01
WO2003040128A1 (en) 2003-05-15
JP2005513004A (ja) 2005-05-12
BR0213977A (pt) 2004-08-31
US6831087B2 (en) 2004-12-14
EP1448547A1 (en) 2004-08-25
CN1585762A (zh) 2005-02-23
US20030119870A1 (en) 2003-06-26
AU2002351816B2 (en) 2008-03-06
CN100516061C (zh) 2009-07-22
DE60203820T2 (de) 2006-02-23
ATE293619T1 (de) 2005-05-15
RU2303037C2 (ru) 2007-07-20

Similar Documents

Publication Publication Date Title
CN108602776B (zh) 用作irak抑制剂的杂芳基化合物及其用途
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
EP1492785B1 (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
AU2002304800B2 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors
JP7692353B2 (ja) マトリプターゼ２阻害剤及びその使用
EP3813819A1 (en) Inhibitors of cyclin-dependent kinases
ES2400695T3 (es) Derivados de quinazolina y piridopirimidina como inhibidores de la cinasa p38
CN102958921B (zh) 一种脲类化合物、其制备方法、其中间体及其应用
JP2009510086A (ja) ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
EA002907B1 (ru) Производные 6-фенилпиридил-2-амина, полезные в качестве ингибиторов nos
WO1994018170A1 (en) Use of phenyl heteroaryl ureas as 5ht2c receptor antagonists and urea compounds
EP1448547B1 (en) Pyridine derivatives as nmda receptor ligands
DE60305332T2 (de) IMIDAZOi1,2-AöPYRIDINE
IE64522B1 (en) Novel benzopyrido piperidine piperdylidene and piperazine compounds compositions methods of manufacture and methods of use
AU2002351816A1 (en) Pyridine Substituted Isoquinoline Derivatives
AU2004273771A1 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (GSK-3)
DE2341965A1 (de) N- eckige klammer auf 1-(omegaphenylalkyl)-piperidyl-4 eckige klammer zu -n-(alpha-pyridyl)-carbonsaeureamide, deren saeureadditionssalze, verfahren zu deren herstellung, sowie deren verwendung als arzneimittel
JPH07502268A (ja) 化学化合物、それらの製法および使用
WO2014160177A2 (en) Quinazoline inhibitors of pi3k
KR20230067669A (ko) 2-아미노-3-카르보닐 이미다조피리딘 및 피라졸로피리딘 화합물
WO1993019062A1 (en) Tetrahydropyridine isoxazoline derivatives
JPS60174778A (ja) Ｎ−ヘテロシクリル−４−ピペリジンアミン
HK1120512A (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors
HK1071360B (en) 2-hydroxy-3-heteroarylindole derivatives as gsk3 inhibitors